Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight

Palatin Technologies Inc. PTN on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide.

Eli Lilly And Co’s LLY tirzepatide is available as Mounjaro and Zepbound for diabetes and weight loss.

Topline data results from the study were highly statistically significant for the study’s primary endpoint, which was percent weight loss in patients for the co-administration of MC4R agonist bremelanotide plus GLP-1/GLP tirzepatide compared to placebo, over the 8-week treatment period.

The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group.

Also Read: Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus

The primary analysis for additive effect demonstrated that:

40% of patients in the co-administered group achieved a 5% reduction in their body weight, compared to 27% for the tirzepatide alone group.
27% of patients in the co-administered group achieved a 6% reduction in their body weight, compared to 13% for the tirzepatide alone group.
19% of patients in the co-administered group achieved a 7% reduction in their body weight, compared to 0% for the tirzepatide alone group.

Over 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration and the tirzepatide-only groups, a common occurrence following the discontinuation of GLP-1/GIP therapy.

The data indicated that weight regain was effectively halted in the MC4R agonist bremelanotide group.

Additionally, co-administration of the MC4R agonist with the GLP-1/GIP therapy showed no increase in safety or tolerability concerns among patients.

Further data analysis is ongoing, including exploratory endpoints such as body composition and body mass index.

Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone treatments, as well as in combination with GLP-1/GIP (incretin therapy), and as monotherapy for multiple genetic obesity disorders.

Investigational New Drug applications are expected to be submitted in the fourth quarter of calendar 2025, with clinical data expected in the first half of 2026.

Price Action: PTN stock is down 14.6% at $0.5656 at the last check Monday.

Read Next: